Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy…
Browsing: Acute Lymphoblastic Leukemia
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Microbiome Effects of Antibodies Can Linger for Up to 60 Days…
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses tUsing Microbiome Transplantation or FMT for RCC They should still benefit from…
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect…
Only one treatment for malignant mesothelioma has been approved since 2003 and rates of the disease are rising worldwide; thus,…
There is currently an array of exciting clinical trials for mesothelioma, investigating cutting-edge treatments in large patient groups. Here, Dean…
There has been a vast increase in our understanding of the pathology of mesothelioma in the past 5 years, which…
Mesothelioma cases are on the rise, in both developed and developing countries. Thus, increased understanding of the underlying mechanisms of…
The first study illustrating the potential of MRI in the diagnosis of prostate cancer was published in 2006. Although there…
The current diagnostic methods for prostate cancer are not always as reliable or accurate as they could be, leading to…
Recent news reports have identified poorer outcomes in cancer patients from the UK compared with those in certain other European…
The take-home message from the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, on MRI for prostate cancer diagnosis was…
The utilization of MRI for the diagnosis of prostate cancer in men at risk is relatively new. In this interview,…
Current practice in the UK requires urologists to refer patients with urological cancer to oncologists for treatment. In this interview,…
Highly anticipated data from the Phase III SPARTAN study (NCT01946204), which investigated apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC), was…
There has previously been no effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC). Now there are several exciting late-phase clinical…
With exciting data from the Phase III SPARTAN (NCT01946204) and PROSPER (NCT02003924) trials of apalutamide and enzalutamide, respectively, for the…
The emergence of an effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is likely to have a paradigm-changing effect on…
Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a disease which had no FDA-approved treatment. Following the completion of the Phase III…
With the emergence of five novel immune checkpoint inhibitors for the treatment of urothelial carcinoma, the key question now arising…
A highly anticipated topic at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, was immune checkpoint inhibitor data…
Immune checkpoint inhibitors for urothelial carcinoma in the relapsed/refractory setting have already been approved and are superseding standard chemotherapy. Now,…
Novel immune checkpoint inhibitors that are entering the clinic are changing the way in which we treat metastatic urothelial carcinoma,…
Minimal residual disease (MRD) monitoring is a promising and controversial topic, with its increasing use in clinical trials being followed…
There was exciting new trial data for the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) from the American Society…
Older acute myeloid leukemia (AML) patients are not typically given intensive cytotoxic chemotherapy due to their fragility and comorbidities. Decitabine…
The outcomes of patients with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) are poor, with no standard therapy. In this…
Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the pilot…
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, was an exciting one for multiple…
Minimal residual disease (MRD) is the major cause of relapse in multiple myeloma (MM), and measurements of its level can…
At the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Graham Jackson, FRCP, FRCPath, MD,…
Copanlisib is a novel PI3K inhibitor, targeting both PI3K-? and PI3K-? isoforms in malignant B-cells. It was granted FDA approval…
Ibrutinib combination therapy in an exciting therapeutic area with great potential. Many recent and ongoing studies are seeking to identify…
Data from the Phase III MURANO study (NCT02005471) in relapsed/refractory chronic lymphocytic leukemia (CLL) was highly anticipated at the American…
Treating lymphoma patients in the relapsed/refractory setting often proves a challenge for physicians. PEP-C (prednisolone, etoposide, procarbazine and cyclophosphamide) is…
In the UK, escalated BEACOPP (escBEACOPP) was introduced as an alternative to ABVD for the treatment of advanced-stage Hodgkin lymphoma…
An exciting new nurse-led rapid access lung cancer clinic has been started in Ceredigion, Wales. Here, the Clinical Nurse Specialist…
This years British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, presented a range of exciting data,…
The role of the nurse in the management and care of patients with cancer is essential one, which is evolving…
Robotic surgery equipment is notoriously expensive, limiting the number of hospitals and surgeons who can utilize this beneficial technology. In…
Where there was previously one primary manufacturer for robotic-assisted surgery machinery, there are now several newcomers on the block. Speaking…
Despite some forms of minimally invasive surgery being performed for some time, we are still lacking the analytical evidence that…
Robotic-assisted thoracic surgery can be combined with other techniques and utilized for a wide range of procedures. Here, Joel Dunning,…
Robotic-assisted surgery is an exciting, innovative area, which is growing and becoming more widespread. Here, Joel Dunning, PhD, FRCS, of…
This is an exciting time for chronic lymphocytic leukemia (CLL) research, with the possibility of chemotherapy-free treatment approaches. In this…
Little is known about TP53 mutations and their association with adverse prognosis and chemotherapy resistance in chronic lymphocytic leukemia (CLL).…
Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses Immune & Combination Therapies Will be Important for Years Because of…
Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses Adverse Effects of Venetoclax and Ibrutinib Only 1 in 50 Patients…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about Drugs to Use if One has Cancer or Clots…
Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses CLARITY Trial Limitations; No Control Group Extrapolated onto the FLAIR Trial…